Federal contract award
75A50124F61017
TASK ORDER ESTABLISHING PHYSICAL AND CHEMICAL COMPATIBILITY (PCC) STUDY FOR ACQUIRED INFLUENZA A/ASTRAKHAN/3212/2020 (H5N8) ANTIGEN COMBINED WITH MF59 ADJUVANT OR AS03 ADJUVANT.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | 75A50122D00002 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $143.8K |
| Current contract value | $143.8K |
| Potential contract value / ceiling | $143.8K |
| Start date | Sep 23, 2024 |
| Current end date | Jul 15, 2025 |
| Potential end date | Jul 15, 2025 |
| Latest award activity | Dec 18, 2024 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 18, 2024 | P00001 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE FROM 9/30/2024-2/27/2025 TO 9/30/2024-7/15/2025. IN ADDITION, CHANGE THE CONTRACTING OFFICER FROM DEITRA WILLIAMS TO JILL JOHNSON (G.1 ) & UPDATE THE COR FROM BEZ |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.